What components are measured in a BNP (B-type natriuretic peptide) assay?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Measured in a BNP Assay

BNP assays measure multiple molecular forms of B-type natriuretic peptide, including the active BNP hormone (BNP 1-32), its precursor proBNP (1-108 amino acids), and the inactive N-terminal fragment NT-proBNP (1-76 amino acids), with significant cross-reactivity between these forms depending on the specific antibody epitopes used in each assay 1, 2.

The Molecular Forms Detected

The BNP assay does not measure a single, pure molecule. Instead, it detects a mixture of related peptides:

  • Active BNP (BNP 1-32): The 32 amino acid biologically active hormone (amino acid residues 77-108 of the precursor)
  • ProBNP (BNP 1-108): The 108 amino acid precursor molecule that splits into BNP and NT-proBNP
  • NT-proBNP (amino acids 1-76): The inactive N-terminal fragment released when proBNP is cleaved

Research demonstrates that proBNP is actually the predominant form measured in most BNP assays, particularly in heart failure patients 3. The proBNP:BNP ratio in patient plasma averages 6.3 (ranging from 1.8 to 10.8), meaning the precursor form comprises the majority of what commercial BNP assays detect 3. High molecular weight BNP (approximately 37 kDa, consistent with proBNP) represents the major immunoreactive component, with a ratio of approximately 1.9:1 compared to the low molecular weight active BNP (approximately 4 kDa) 4.

Why This Cross-Reactivity Occurs

The cross-reactivity between these molecular forms stems from the antibody recognition sites used in commercial assays 1. For BNP measurement, assays typically use:

  • One antibody binding to the ring structure of BNP
  • A second antibody binding to either the carboxy-terminal or amino-terminal end

Since proBNP contains the complete BNP sequence plus the NT-proBNP sequence, antibodies designed to detect BNP will inevitably recognize proBNP as well 1. This is not a flaw but rather an inherent characteristic of sandwich immunoassays targeting these peptides.

Clinical Implications

The fact that commercial BNP assays measure predominantly proBNP rather than the active hormone has important clinical ramifications 5. ProBNP itself lacks biological activity and must be cleaved by specific plasma proteases to generate active BNP. In heart failure patients, this peripheral processing may be impaired, meaning a substantial portion of measured "BNP" may be biologically inactive precursor 5.

The molar concentration of NT-proBNP in patient plasma is approximately 10 times higher than proBNP, which itself is present at much higher concentrations than active BNP 3. This explains why NT-proBNP assays often show higher absolute values than BNP assays in the same patient.

Assay-Specific Variations

Different commercial BNP assays can yield results varying by 1.2- to 7.2-fold for the same sample due to differences in antibody epitope specificity 6. Guidelines emphasize that results should be reported in ng/L rather than pmol/L until clinically relevant molecules are clearly determined and reference systems are standardized 1.

Critical preanalytical factors affecting what is measured include:

  • Sample type: EDTA plasma is required for BNP; serum or heparin plasma for NT-proBNP (EDTA gives 8-10% negative bias for NT-proBNP) 1
  • Storage conditions: Samples should be collected in iced tubes and processed rapidly to prevent in vitro degradation 1
  • Glycosylation and proteolytic cleavage: Both processes affect BNP recognition by antibodies and contribute to differences in stability between assays 1

Related Questions

In a patient presenting with neurological symptoms and an elevated B-type natriuretic peptide (BNP), what is the significance and recommended management?
How should a 73-year-old man with a B-type natriuretic peptide level of 980 pg/mL be evaluated and managed?
In a 73-year-old man with a B-type natriuretic peptide level of 958 pg/mL, what does this indicate?
What does an elevated B-type natriuretic peptide of 249 pg/mL indicate in a 2‑year‑old female presenting with respiratory distress, and how should she be managed?
What is the appropriate evaluation and management for a patient with elevated B-type natriuretic peptide (BNP) without cardiomegaly?
Why does insulin deficiency in diabetes mellitus not lead to decreased cholesterol synthesis despite the expected down‑regulation, given that increased acetyl‑CoA promotes up‑regulation?
In a 4‑month‑old infant being treated for presumed meningitis with intravenous ampicillin and cefotaxime, who is clinically improving, blood cultures are negative, vital signs are stable, afebrile since day 2, and on day 9 there is no peripheral IV access despite multiple attempts, should the antibiotics be switched to intramuscular administration to complete the 10‑day course, or should IV therapy be continued (e.g., via a PICC line)?
When should one versus two double‑strength tablets of sulfamethoxazole/trimethoprim be used for abdominal wall cellulitis?
In a 4-month-old infant with presumed bacterial meningitis, can ampicillin be given intramuscularly?
What are the possible causes of head pain radiating to the neck?
What is the most likely diagnosis for a patient with lower back pain radiating to the right buttock, iliac crest, lateral hip, and down the right leg after a lifting-and-twisting injury?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.